 Cocrystal Pharma, Inc. NASDAQ: COCP, Cocrystal or the Company, a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today provided an update on the impact of the COVID-19 global pandemic on its preclinical and clinical development programs. We have reprioritized development activities to accelerate the advancement of our preclinical COVID-19 program, which we recently established as a result of our license agreements with Kansas State University Research Foundation KSRF, commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. 